J Korean Diabetes > Volume 14(3); 2013 > Article
The Journal of Korean Diabetes 2013;14(3):120-124.
DOI: https://doi.org/10.4093/jkd.2013.14.3.120    Published online September 30, 2013.
인크레틴 계열 약제의 새로운 기전
Pleiotropic Effects of an Incretin Hormone.
Seungjoon Oh
Division of Endocrinology & Metabolism, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea. orqwic@chollian.net
The incretin hormones glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have recently received much attention for their roles in type 2 diabetes therapy. GLP-1 stimulated insulin secretion in a glucose-dependent manner and is secreted by intestinal L cells. It also regulates blood glucose concentration, stomach motility, appetite, and body weight. These actions are mediated through G-protein-coupled receptors highly expressed on pancreatic beta cells and also exert indirect metabolic actions. Activation of GLP-1 receptors also produces nonglycemic effects in various tissues. The pleiotropic effects of GLP-1 have been recently reported. The mechanisms identified in preclinical studies have potential translational relevance for the treatment of disease. Here, the nonglycemic effects of GLP-1, especially those on the liver, central nervous system, and bone, were reviewed.
Key Words: Glucagon-like peptide 1, Incretins, Incretin/therapeutic use

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer